TY - JOUR
T1 - A technology evaluation of Annovera
T2 - a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year
AU - Micks, Elizabeth A.
AU - Jensen, Jeffrey T.
N1 - Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/6/2
Y1 - 2020/6/2
N2 - Introduction: The segesterone acetate and ethinyl estradiol contraceptive vaginal ring (SA/EE CVR) was FDA-approved in August 2018 and is now available in the U.S. The CVR is placed vaginally for 21 days followed by a 7-day ring-free interval, when withdrawal bleeding typically occurs. One ring can be used for up to a year (13 cycles). Areas covered: This review summarizes this novel method of contraception, including the delivery system and the hormonal components. We describe the potential market, how it is used, the pharmacokinetic properties of the device, and results of clinical trials including efficacy, bleeding profile, acceptability, and safety. Expert opinion: The SA/EE CVR represents the first long-lasting user-controlled hormonal contraceptive device. The bleeding pattern is highly favorable and consistent over the entire year and is associated with very low discontinuation. Efficacy and safety are similar to other methods of combined hormonal contraceptives. Unscheduled ring removals increase the risk of failure. Further studies are needed to evaluate continuous use of the ring for greater than 21 days, and potential non-contraceptive benefits of the ring such as reduced menstrual bleeding.
AB - Introduction: The segesterone acetate and ethinyl estradiol contraceptive vaginal ring (SA/EE CVR) was FDA-approved in August 2018 and is now available in the U.S. The CVR is placed vaginally for 21 days followed by a 7-day ring-free interval, when withdrawal bleeding typically occurs. One ring can be used for up to a year (13 cycles). Areas covered: This review summarizes this novel method of contraception, including the delivery system and the hormonal components. We describe the potential market, how it is used, the pharmacokinetic properties of the device, and results of clinical trials including efficacy, bleeding profile, acceptability, and safety. Expert opinion: The SA/EE CVR represents the first long-lasting user-controlled hormonal contraceptive device. The bleeding pattern is highly favorable and consistent over the entire year and is associated with very low discontinuation. Efficacy and safety are similar to other methods of combined hormonal contraceptives. Unscheduled ring removals increase the risk of failure. Further studies are needed to evaluate continuous use of the ring for greater than 21 days, and potential non-contraceptive benefits of the ring such as reduced menstrual bleeding.
KW - Annovera
KW - combined hormonal contraception
KW - vaginal ring contraception
UR - http://www.scopus.com/inward/record.url?scp=85085016511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085016511&partnerID=8YFLogxK
U2 - 10.1080/17425247.2020.1764529
DO - 10.1080/17425247.2020.1764529
M3 - Article
C2 - 32410464
AN - SCOPUS:85085016511
SN - 1742-5247
VL - 17
SP - 743
EP - 752
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 6
ER -